Among biotech companies, the competition between Cara Therapeutics Inc (CARA) and Intellia Therapeutics Inc (NTLA) has been an intriguing one. The two companies had been on the same level as far as the market cap goes during most of the year so far.
But Cara has now pulled ahead by as much as $150 million following positive data from its lead product candidate. That being said, it is also important to keep in mind that if an investor is looking at a long term investment, then the disparity in market cap between the two companies is a minor. Here’s a look at the pros and cons of Cara and Intellia.
Cara Therapeutics (CARA)
Cara Therapeutics is currently on the rise. Its lead product candidate Korsuva injection delivered highly encouraging results in its Phase 3 trial. It’s now believed that it would not be long before Cara has its first product on the market.
It is meant for the treatment of moderate-to-severe chronic kidney disease-associated pruritus. According to reports, the results were great. Another late-stage test is going to be conducted soon. The results could be announced by the end of this year. If Korsuve is approved, then it will be marketed by Fresenius Medical Care and Vifor Pharma Group.
Cara has entered joint ventures with those companies to market the product in the United States, Japan, and South Korea. An oral version of Korsuva is also in the pipeline and could prove to be another important development.
Intellia Therapeutics (NTLA)
Intellia Therapeutics (INTA) is involved in creating CRISPR gene editing therapies. It is a segment that has a lot of promise in the future. Even though the company is some years away from having anything on the market, the promise of gene editing therapy is exciting. So much so that Intellia has already found partners in big-ticket firms like Regeneron and Novartis.
Intellia is expected to file for FDA approval for the clinical study into its lead product NLTA-2001 in 2020. It is meant for the treatment of transthyretin amyloidosis, an uncommon genetic disease. Studies into the products have proven to be promising so far. The company is also working on a product to treat myeloid leukemia.
Now when it comes to choosing between Cara and Intellia, experts believe that the former could a better company. It’s already on the verge of having an approved product on the market. Intellia, on the other hand, is likely to be some years away from winning approval.
Are These Companies On Your Stocks To Watch List This Week?
The biotechnology sector has been on a mini-bull run this month. In fact, for the 7th consecutive trading day on Friday, the Biotech ETF – IBB- made yet another new high during that period. I’m not talking about all-time highs or 52-week highs. I’m talking about the fact that for 7 straight trading sessions, the IBB booked a higher high than its previous session.
So what could this mean for the sector? Obviously today (10-21) will dictate the initial pace for the new week. However, thanks to this common trend, it can be suggested that biotech is in a mini-bull rally. Given that, people are starting to turn their heads toward the sector and healthcare as a whole. In addition to that, small caps have been in their own micro-rally during this same period.
If you look at the Russell 2000 Small-Cap ETF – IWM – you’ll notice a similar uptick. Given this information, here’s a look at 3 small-cap biotech companies that may warrant a closer look after recent developments.
Biotech Stock To Watch #1: GT Biopharma Inc. (GTBP)
For most of October, GT Biopharma (GTBP) has been in a relatively consistent uptrend. Starting on October 4, GTBP stock has managed to jump from $0.125 to highs of $0.1995 last week. Shares closed the week at $0.16 on October 18. So what’s happened with GT Biopharma this month?
The company may have benefited from the attention being placed on companies with targeted therapies. Specifically, GT Biopharma (GTBP) announced that Tim Schacker, M.D., Jeffrey S. Miller, M.D., and their colleagues at the University of Minnesota presented data during a poster session. The presentation was held at the 18th meeting of the Society for Natural Immunity in Luxembourg discussing their design of an HIV-TriKE™ containing an antigen-binding fragment from a broadly neutralizing antibody targeting the HIV-Env protein.
But it wasn’t just a presentation alone; GT Biopharma’s results could be something raising eyebrows and here’s why. Despite the use of anti-retroviral drugs, infected individuals retain reservoirs of latent HIV-infected cells that, upon cessation of antiretroviral drug therapy, can reactivate and re-establish an active HIV infection.
However, Research findings from Dr. Schacker’s and Dr. Miller’s laboratories show enhanced NK cell cytokine production and the killing of infected targets expressing HIV-Env when incubated with the HIV-TriKE™. Since the publication of these results, GTBP has been in this previously mentioned uptrend. Can it continue this week?
Biotech Stock To Watch #2: Sienna Biopharmaceuticals, Inc. (SNNA)
Second, on this list of biotech stocks, Sienna Biopharmaceuticals, Inc. (SNNA) has found a more bullish trend to close out last week. This clinical-stage biopharmaceutical company recently announced that it has filed a Premarket Notification 510(k) submission to the FDA. This was for its SNA-001, a topical pre-treatment to standard laser devices to remove unwanted light hair. Sienna has also received an acknowledgement from FDA that the submission has been accepted.
Why is this important to know? The purpose of the 510(k) notification is to allow for commercial use of SNA-001, in conjunction with an 810 nm Diode laser, for the removal of unwanted white, gray, blonde, light red and light brown hair in women or men. According to the company, people with white, gray, blonde and red hair, for whom lasers are ineffective, have generally been limited to using waxing and razors to remove their unwanted light hair.
Biotech Stock To Watch #3: Aevi Genomic Medicine, Inc. (GNMX)
The third small-cap biotech stock on this list is Aevi Genomic Medicine, Inc. (GNMX). Late Friday, shares of this biotech penny stock saw a second surge that triggered a bullish close to finish the week. The company focuses on genomic medicine to translate genetic discoveries into novel therapies. Last week was a pivotal week for the company.
Aevi announced that the Nasdaq Hearings Panel has agreed to the transfer of the Company’s shares to the Nasdaq Capital Market. On top of that, it granted the Company until February 3, 2020, to gain and evidence compliance of the Nasdaq Capital Market continued listing requirements.
In order to meet the Nasdaq Capital Market continued listing requirements, the Company must demonstrate a closing bid price of at least $1.00 for 10 prior consecutive trading days and both publicly announce and inform the Nasdaq Hearings Panel that the Company has stockholders’ equity greater than $2.5 million on or before February 3, 2020. Will Friday’s trend continue this week?
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019, to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer.
3 Penny Stocks Looking To Change The Biotech Industry
The world of biotech investing can be tricky. That’s particularly true when it comes to small-cap stocks in the industry. These companies often have terrific science, but no profits and little revenue; if any at all. But biotech stocks can offer true potential for investors who know what to look for.
Perhaps the best strategy for gaining exposure to this space is to look at early-stage, small-cap biotechs. By doing so, you put yourself at the front-line for cutting edge, experimental companies that could one day hit it big. Given this, here are 3 small-cap biotechs working to evolve in the biotech industry.
GT Biopharma Inc. (GTBP)
One company making groundbreaking developments in the biotechnology field is GT Biopharma Inc. (GTBP). GT Biopharma Inc. is an immune-oncology biotech company determined to create new treatments for cancer. In order to do this, the company leverages its proprietary TriKE technology to develop its pipeline. As of now, GT Biopharma has 6 treatment plans undergoing the clinical trial process.
So, what exactly is this TriKE technology platform? TriKE is actually an acronym for tri-specific killer engagers that are made to target NK’s or natural killer and tumor cells. Once they target NK cells, it binds to the CD16 receptor which makes a longer and stronger response compared to current treatment methods.
One use of TriKE has been to develop a way to target the HIV-Env protein. The design to do this is known as HIV-TriKE. As a matter of fact, the company recently announced data that showed the effectiveness of HIV-TriKE. It was shown that it enhanced NK cell cytokine production and effectively killed infected targets with HIV-Env.
“We are pleased to see how the TriKE™ technology is able to be extended to the treatment of infectious disease and is able to kill HIV in the reservoir.” Mr. Cataldo further stated, “We believe the HIV-TriKE™ will become part of a scalable and curative therapeutic strategy,” expressed Anthony Cataldo, CEO and Chairman of GE Biopharma.
Conatus Pharmaceuticals Inc. (CNAT)
This next biotechnology company is known as Conatus Pharmaceuticals Inc. (CNAT). This company’s focus is different compared to GT Biopharma. It aims to treat chronic diseases that have a large unmet need. Its lead product candidate CTS-2090, inhibits IL-1β which treats inflammatory diseases.
In terms of news releases, the company has been slightly lackluster over the last two months. However, in early August Conatus released its Q2 financials which showed some profitability promise in its income statement.
Revenues increased and expenses decreased in Q2 2019 compared to Q2 2018 which significantly reduced the company’s net loss by $3.8 million. One potential hindrance factor in the financials could be Conatus’ consistently declining free cash flow.
Nuvectra Corporation (NVTR)
To top things off, we have a neurostimulation company known as Nuvectra Corporation (NVTR). The company has a commercial product called Algovita Spinal Cord Stimulation which treats chronic pain of the trunk and limbs. In addition to this, Nuvectra is awaiting FDA pre-market approval for its Virtis Sacral Neuromodulation which treats chronic urinary retention and overstive bladders.
Compared to Conatus, Nuvectra has produced recent news that investors can sink their teeth into. First off, the company appointed Jennifer Kosharek as CFO around a month ago. This is a strong appointment thanks to her 15+ years of accounting experience and other leadership positions with Nuvectra.
Furthermore, the company recently submitted its supplementary chemical composition and biocompatibility data to the FDA to support Virtis’ pre-market approval.
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma Inc. (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma Inc. (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma Inc. (GTBP). Full Disclaimer Click Here
Are These Biotech Names On Your October Watch List?
Over the past two decades, the biotech sector has been one of the best sectors to watch. If experts are to be believed, then it is likely to continue to be a hot sector for the foreseeable future. However, biotech stocks require research and that can help when it comes to making a list of biotech stocks.
Once that is done, the investor needs to track the companies closely. Then it’s easier to decide upon the best course of action. Here is a look at three biotechnology penny stocks this month.
Biotech Stocks To Watch: PharmaCyte Biotech (PMCB)
If you’re looking at PharmaCyte Biotech (PMCB) at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug Application for the FDA. Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.
David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Though there has been a targeted focus on Pancreatic cancer with PharmaCyte, its diabetes application may also have promise according to Judd.
“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this. Selecting the right cell line to become our leading product candidate to treat diabetic patients in need of insulin is key to the success of PharmaCyte’s Diabetes Program.”
Over the last week, shares of PMCB stock have jumped from $0.0319 to highs of $0.0367 on Friday.
Biotech Stocks To Watch: Hepion Pharmaceuticals (HEPA)
The next biotech stock to watch is Hepion Pharmaceuticals Inc (NASDAQ:HEPA). The company is involved in manufacturing medicines meant for liver conditions emanating from non-alcoholic reasons. The company announced that its research article has been published by the highly influential peer-reviewed journal, the Journal of Pharmacology and Experimental Therapeutics.
The paper in question is titled “A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.” The study shows that Hepion’s product CRV431 could well be a solution for treating chronic diseases of the liver. The paper also stated that the medicine is suited to address a range of therapeutic needs.
Once the news broke, the company’s stock started soaring and soared over 43% at $3.58, well off the session high of $5.59.
Biotech Stocks To Watch: Protalix Biotherapeutics (PLX)
The other biotech stock that broke out more this week is Protalix Biotherapeutics Inc (NYSE:PLX). The company released data from the BRIDGE Phase 3 clinical study of its product PRX-102 and the revelations have proven to be highly encouraging. Out of a total of 22 patients who had been enrolled for the study, the data was gleaned from 16 of them.
The patients in question had been treated with PRX-102 for 12 months. The medicine is meant for treating Fabry disease and it has been revealed that there was an improvement in the function of kidneys in the patients. The stock soared by as much as 75% on Thursday and should definitely be on the watch lists of most investors.
Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Full Disclaimer Here.
Join Our Newsletter
Get stock alerts, news & trending stock alerts straight to your inbox!
We keep all user information pricate & promise to never spam.*
Search Stock Price (StockPrice.com)
Featured7 days ago
What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World!
Biotechnology2 weeks ago
Biotech Stocks In Focus Amid New Wave Of Drug Delivery
Biotechnology1 week ago
3 Top Biotech Stocks To Monitor In October
Biotechnology6 days ago
Healthcare Stocks To Watch Amid Bullish Earnings
Biotechnology2 weeks ago
Top Biotechnology Stocks To Watch After Latest News
Biotechnology5 days ago
Biotech Stocks To As Sector ETF’s Climb Higher
Biotechnology4 days ago
Biotech ETF’s Just Hit New Highs: 3 Stocks To Watch
Biotechnology2 weeks ago
Biotechnology Stocks Gaining Ground In October; What To Watch